We’ve learned a lot from lymphocytic choriomeningitis virus—now the time has come to fight it
LJI scientists share high-resolution view of the lymphocytic choriomeningitis virus (LCMV) glycoprotein together with a neutralizing antibody
Lab Saphire
LJI scientists uncover the structure and function of Inmazeb, the first FDA-approved drug for Ebola virus infection
New findings emphasize the benefits of antibody cocktails over monotherapy approaches
Durable SARS-CoV-2 antibodies bind to two viral targets at once
"Bivalent" antibodies can continue to neutralize Omicron and Omicron lineages
New Lassa fever therapy may be on the horizon
Three rare antibodies, combined in a "cocktail," are effective in fighting Lassa virus
Putting the brakes on “budding” viruses
New measles, Nipah research offers a window into viral assembly
LJI scientists discover clue to stopping Lassa virus infection
New study shows how new therapies might target Lassa and Ebola viruses
Rethinking the rabies vaccine
LJI scientists, in collaboration with researchers from the Institut Pasteur in France, capture new high-resolution view of rabies virus, revealing potential vaccine targets
The sky, the sea, and Ebola virus
Jingru Fang shares how her Ph.D. research inspired a vivid painting
Targeting a human protein may stop Ebola virus in its tracks
To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase.
Op-Ed: What will it take to make a universal COVID vaccine?
As California emerges from Omicron, other places are again in lockdown or facing record caseloads after trying and failing to
Promising antibody cocktail takes on Ebola virus—and its deadly cousin
LJI team uncovers how one odd antibody does some heavy lifting
Erica Ollmann Saphire receives $2.6 million grant to collaborate on pan-coronavirus vaccine
La Jolla Institute scientists team up with Brigham and Women's Hospital to guide the development of vaccines against the coronavirus family
Lungs of COVID-19 survivors teem with virus-fighting ‘memory’ cells
Even elderly survivors show a strong, persistent immune memory
From Alpha to Epsilon: Consortium study illuminates surfaces of Spike most resistant to antibody escape
LJI-led Coronavirus Immunotherapeutic Consortium identifies antibody 'communities' with power to stop SARS-CoV-2 variants
A biochemist takes on Lassa virus
Adrian Enriquez, Ph.D., has a different way of looking at viruses
The new CEO of the La Jolla Institute for Immunology ascended by lifting others
Erica Ollman Saphire brings together scientific competitors to find new antibody therapeutics for COVID-19.
Shape-shifting Ebola virus protein exploits human RNA to change shape
New study highlights VP40 as a promising therapeutic target
Erica Ollmann Saphire appointed president and CEO of La Jolla Institute for Immunology
La Jolla, CA—Erica Ollmann Saphire, Ph.D., has been appointed President and CEO of La Jolla Institute for Immunology (LJI), the Institute announced today.
Leinco Technologies, Inc., and La Jolla Institute for Immunology announce license agreement to develop novel COVID-19 diagnostic tools
LA JOLLA, CA— La Jolla Institute for Immunology (LJI), one of the leading research organizations dedicated to studying the immune system announced today that it has signed a licensing agreement with Leinco Technologies, Inc., a premier developer and manufacturer of leading-edge recombinant proteins,…
Experts torn over changing vaccine doses to speed up lagging rollout
To speed inoculations, the U.S. plans to release all available vaccine doses and open access to anyone over 65. Others suggest straying from recommended doses or intentionally delaying boosters. The best way forward remains uncertain.
Erica Ollmann Saphire named Scientist of the Year by ARCS San Diego
Award recognizes Saphire's leadership in global effort against COVID-19
3 things we know (and 3 we don’t) about Pfizer’s initial COVID-19 vaccine results
San Diego scientists and trial participants are cautiously optimistic after early reports that Pfizer’s COVID-19 vaccine is highly effective
LJI Professor Erica Ollmann Saphire awarded $6.4 million for international efforts to beat COVID-19
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded more than $6.4 million to Dr. Saphire to support research toward COVID-19 antibody therapeutics.
La Jolla Institute for Immunology receives $1 million from GHR Foundation in support of COVID-19 research
LA JOLLA, CA – La Jolla Institute for Immunology (LJI) has announced a $1 million gift from GHR Foundation, an independent global philanthropy based in Minneapolis, MN. This significant gift will support the work of the Coronavirus Immunotherapy Consortium (CoVIC), a global partnership headquartered…
From Wuhan to San Diego—How a mutation on the novel coronavirus has come to dominate the globe
A small variation has made the novel coronavirus fitter—but not more deadly
LJI’s Erica Ollmann Saphire receives $100,000 Fast Grant for COVID-19 research
Antibody therapeutics will likely be a critical tool for protecting frontline healthcare workers and those at most risk of SARS-CoV-2 infection
La Jolla Institute for Immunology acquires Berkeley Lights Beacon® platform
The Beacon optofluidic technology will be used to speed the identification of lifesaving treatments for deadly viruses including Ebola, Lassa and others.
Lassa virus’ soft spot revealed
Detailed structural studies provide blueprint for the development of potent therapeutics and vaccines
La Jolla Institute-led consortium awarded up to $35 million by NIH
The grant establishes the global Viral Immunotherapeutic Consortium to develop new treatments for Ebola, Lassa and other viral threats
Leading Structural Immunologist Erica Ollmann Saphire will join La Jolla Institute for Immunology
"She is a truly exceptional scientist, who uses molecular insights to bring together scientists and policymakers for scientific advancement and social change"
